Drug Profile
PC 1358
Alternative Names: TricominLatest Information Update: 22 Oct 2003
Price :
$50
*
At a glance
- Originator ProCyte Corporation
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alopecia
Most Recent Events
- 30 Nov 2000 Discontinued - Phase-II for Alopecia in USA (Topical)
- 11 Jun 1997 Discontinued-Preclinical for Alopecia in Japan (Topical)
- 21 May 1997 A study has been added to the therapeutic trials section (FDC Reports 1997 May)